AWM
ANIP icon

AE Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

AE Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,624
Closed -$501K – 2050
2023
Q3 		$501K Sell
8,624
-796
-8% -$45.9K ﹤0.01% 1384
2023
Q2 		$507K Buy
+9,420
New +$418K ﹤0.01% 1390
2019
Q4 		– Sell
-3,407
Closed -$248K – 1129
2019
Q3 		$248K Sell
3,407
-1,584
-32% -$119K 0.01% 852
2019
Q2 		$410K Buy
4,991
+1,590
+47% +$113K 0.01% 642
2019
Q1 		$240K Buy
+3,401
New +$200K 0.02% 539

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AE Wealth Management's ANIP Position: Q4 2023 in Review

AE Wealth Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 8,624 shares — an estimated $501K sold.

AE Wealth Management first reported a position in ANIP in Q1 2019 and held it in 5 quarters. The position peaked at $507K in Q2 2023. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

  • AE Wealth Management reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • AE Wealth Management sold 8,624 ANI Pharmaceuticals shares in Q4 2023, an estimated $501K.
  • AE Wealth Management first reported a position in ANI Pharmaceuticals in Q1 2019 and held it in 5 quarters.
  • AE Wealth Management's ANI Pharmaceuticals position peaked at $507K in Q2 2023.
  • 181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on AE Wealth Management's 13F filing for Q4 2023, filed 14 Feb 2024.